Previous close | 60.00 |
Open | 60.00 |
Bid | 57.10 |
Ask | 62.00 |
Strike | 50.00 |
Expiry date | 2024-01-19 |
Day's range | 60.00 - 60.00 |
Contract range | N/A |
Volume | |
Open interest | 4 |
Bagsværd, Denmark, 8 August 2022 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated per
Novo Nordisk (NVO) missed estimates for earnings in the second quarter of 2022 while revenues beat the same, driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.